The post-market review of COPD medicines recommended by the PBAC in August is now open for public comment. The review was given the green light following concerns about the multiple use of a number of new combinations available on the PBS, including long-acting muscarinic antagonist (LAMA)/LABA and LABA/inhaled corticosteroid (ICS) combinations. The terms of reference ...
Already a member?
Enter your email to keep reading.